Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV004075193 | SCV003532698 | uncertain significance | not specified | 2021-07-16 | criteria provided, single submitter | clinical testing | The c.1916G>C (p.G639A) alteration is located in exon 4 (coding exon 3) of the NYNRIN gene. This alteration results from a G to C substitution at nucleotide position 1916, causing the glycine (G) at amino acid position 639 to be replaced by an alanine (A). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Labcorp Genetics |
RCV005099471 | SCV005810624 | uncertain significance | not provided | 2024-12-12 | criteria provided, single submitter | clinical testing | This sequence change replaces glycine, which is neutral and non-polar, with alanine, which is neutral and non-polar, at codon 639 of the NYNRIN protein (p.Gly639Ala). This variant is present in population databases (rs376129072, gnomAD 0.2%), and has an allele count higher than expected for a pathogenic variant. This variant has not been reported in the literature in individuals affected with NYNRIN-related conditions. ClinVar contains an entry for this variant (Variation ID: 2211576). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Prevention |
RCV003973730 | SCV004787321 | likely benign | NYNRIN-related disorder | 2022-03-13 | no assertion criteria provided | clinical testing | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). |